Entrada Therapeutics (NASDAQ:TRDA) Insider Sells $398,708.73 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 25,907 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $15.39, for a total value of $398,708.73. Following the completion of the sale, the insider owned 216,317 shares of the company’s stock, valued at $3,329,118.63. This represents a 10.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Entrada Therapeutics Trading Up 8.9%

NASDAQ TRDA traded up $1.29 on Monday, reaching $15.79. The company had a trading volume of 426,082 shares, compared to its average volume of 173,892. The stock’s 50 day moving average is $12.72 and its 200-day moving average is $10.75. Entrada Therapeutics, Inc. has a 52 week low of $4.93 and a 52 week high of $16.00.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) EPS for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.38. The business had revenue of $1.30 million during the quarter, compared to the consensus estimate of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%. Research analysts forecast that Entrada Therapeutics, Inc. will post -4.22 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on TRDA. Weiss Ratings restated a “sell (d)” rating on shares of Entrada Therapeutics in a report on Friday, March 27th. Oppenheimer increased their price target on Entrada Therapeutics from $21.00 to $23.00 and gave the stock an “outperform” rating in a report on Monday, April 6th. Wall Street Zen downgraded Entrada Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Guggenheim upgraded Entrada Therapeutics to a “strong-buy” rating in a report on Wednesday, February 11th. Finally, Cantor Fitzgerald began coverage on Entrada Therapeutics in a report on Wednesday, April 1st. They issued an “overweight” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Entrada Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $19.00.

Institutional Investors Weigh In On Entrada Therapeutics

Several large investors have recently modified their holdings of TRDA. Baker BROS. Advisors LP boosted its position in shares of Entrada Therapeutics by 4.3% during the fourth quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock worth $52,148,000 after buying an additional 206,911 shares during the period. Wellington Management Group LLP boosted its position in shares of Entrada Therapeutics by 9.5% during the fourth quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock worth $10,740,000 after buying an additional 90,339 shares during the period. Millennium Management LLC boosted its position in shares of Entrada Therapeutics by 391.2% during the third quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock worth $4,852,000 after buying an additional 666,287 shares during the period. Geode Capital Management LLC boosted its position in shares of Entrada Therapeutics by 7.2% during the second quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock worth $4,245,000 after buying an additional 42,479 shares during the period. Finally, State Street Corp boosted its position in shares of Entrada Therapeutics by 2.0% during the fourth quarter. State Street Corp now owns 508,789 shares of the company’s stock worth $5,230,000 after buying an additional 10,174 shares during the period. 86.39% of the stock is currently owned by institutional investors.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.